2ew5 › Citations

Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: reverse docking, enzymatic assay, and X-ray crystallography validation.

Cai J, Han C, Hu T, Zhang J, Wu D, Wang F, Liu Y, Ding J, Chen K, Yue J, Shen X, Jiang H
Protein Sci 15 2071-81 (2006)
Related entries: 2ew6, 2ew7

Cited: 50 times
EuropePMC logo PMID: 16882991

Abstract

Colonization of human stomach by the bacterium Helicobacter pylori is a major causative factor for gastrointestinal illnesses and gastric cancer. However, the discovery of anti-H. pylori agents is a difficult task due to lack of mature protein targets. Therefore, identifying new molecular targets for developing new drugs against H. pylori is obviously necessary. In this study, the in-house potential drug target database (PDTD, http://www.dddc.ac.cn/tarfisdock/) was searched by the reverse docking approach using an active natural product (compound 1) discovered by anti-H. pylori screening as a probe. Homology search revealed that, among the 15 candidates discovered by reverse docking, only diaminopimelate decarboxylase (DC) and peptide deformylase (PDF) have homologous proteins in the genome of H. pylori. Enzymatic assay demonstrated compound 1 and its derivative compound 2 are the potent inhibitors against H. pylori PDF (HpPDF) with IC50 values of 10.8 and 1.25 microM, respectively. X-ray crystal structures of HpPDF and the complexes of HpPDF with 1 and 2 were determined for the first time, indicating that these two inhibitors bind well with HpPDF binding pocket. All these results indicate that HpPDF is a potential target for screening new anti-H. pylori agents. In addition, compounds 1 and 2 were predicted to bind to HpPDF with relatively high selectivity, suggesting they can be used as leads for developing new anti-H. pylori agents. The results demonstrated that our strategy, reverse docking in conjunction with bioassay and structural biology, is effective and can be used as a complementary approach of functional genomics and chemical biology in target identification.

Articles - 2ew5 mentioned but not cited (3)

  1. Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: reverse docking, enzymatic assay, and X-ray crystallography validation. Cai J, Han C, Hu T, Zhang J, Wu D, Wang F, Liu Y, Ding J, Chen K, Yue J, Shen X, Jiang H. Protein Sci 15 2071-2081 (2006)
  2. Protein Targets of Frankincense: A Reverse Docking Analysis of Terpenoids from Boswellia Oleo-Gum Resins. Byler KG, Setzer WN. Medicines (Basel) 5 E96 (2018)
  3. Expression, crystallization and preliminary X-ray crystallographic analysis of peptide deformylase from Campylobacter jejuni. Tran HT, Pham TV, Ngo HP, Hong MK, Ahn YJ, Kang LW. Acta Crystallogr Sect F Struct Biol Cryst Commun 69 1120-1122 (2013)


Reviews citing this publication (19)

  1. The value of natural products to future pharmaceutical discovery. Baker DD, Chu M, Oza U, Rajgarhia V. Nat Prod Rep 24 1225-1244 (2007)
  2. Computational drug discovery. Ou-Yang SS, Lu JY, Kong XQ, Liang ZJ, Luo C, Jiang H. Acta Pharmacol Sin 33 1131-1140 (2012)
  3. The chemical basis of pharmacology. Keiser MJ, Irwin JJ, Shoichet BK. Biochemistry 49 10267-10276 (2010)
  4. Structure-Based Approaches to Target Fishing and Ligand Profiling. Rognan D. Mol Inform 29 176-187 (2010)
  5. Computational/in silico methods in drug target and lead prediction. Agamah FE, Mazandu GK, Hassan R, Bope CD, Thomford NE, Ghansah A, Chimusa ER. Brief Bioinform 21 1663-1675 (2020)
  6. Reverse docking: a powerful tool for drug repositioning and drug rescue. Kharkar PS, Warrier S, Gaud RS. Future Med Chem 6 333-342 (2014)
  7. Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds. Huang H, Zhang G, Zhou Y, Lin C, Chen S, Lin Y, Mai S, Huang Z. Front Chem 6 138 (2018)
  8. Using reverse docking for target identification and its applications for drug discovery. Lee A, Lee K, Kim D. Expert Opin Drug Discov 11 707-715 (2016)
  9. Computational methods for drug design and discovery: focus on China. Zheng M, Liu X, Xu Y, Li H, Luo C, Jiang H. Trends Pharmacol Sci 34 549-559 (2013)
  10. In-silico studies in Chinese herbal medicines' research: evaluation of in-silico methodologies and phytochemical data sources, and a review of research to date. Barlow DJ, Buriani A, Ehrman T, Bosisio E, Eberini I, Hylands PJ. J Ethnopharmacol 140 526-534 (2012)
  11. Identification of Similar Binding Sites to Detect Distant Polypharmacology. Jalencas X, Mestres J. Mol Inform 32 976-990 (2013)
  12. Discovery of structurally diverse and bioactive compounds from plant resources in China. Yang SP, Yue JM. Acta Pharmacol Sin 33 1147-1158 (2012)
  13. The potential role of in silico approaches to identify novel bioactive molecules from natural resources. Olğaç A, Orhan IE, Banoglu E. Future Med Chem 9 1665-1686 (2017)
  14. Proteome-scale docking: myth and reality. Rognan D. Drug Discov Today Technol 10 e403-9 (2013)
  15. Chinese Herbal Medicine Meets Biological Networks of Complex Diseases: A Computational Perspective. Gu S, Pei J. Evid Based Complement Alternat Med 2017 7198645 (2017)
  16. Novel Helicobacter pylori therapeutic targets: the unusual suspects. Duckworth MJ, Okoli AS, Mendz GL. Expert Rev Anti Infect Ther 7 835-867 (2009)
  17. In silico Methods for Identification of Potential Therapeutic Targets. Zhang X, Wu F, Yang N, Zhan X, Liao J, Mai S, Huang Z. Interdiscip Sci 14 285-310 (2022)
  18. From Diospyros kaki L. (Persimmon) Phytochemical Profile and Health Impact to New Product Perspectives and Waste Valorization. Direito R, Rocha J, Sepodes B, Eduardo-Figueira M. Nutrients 13 3283 (2021)
  19. In Silico Approach for Phytocompound-Based Drug Designing to Fight Efflux Pump-Mediated Multidrug-Resistant Mycobacterium tuberculosis. Biswas SS, Browne RB, Borah VV, Roy JD. Appl Biochem Biotechnol 193 1757-1779 (2021)

Articles citing this publication (28)

  1. SwissDock, a protein-small molecule docking web service based on EADock DSS. Grosdidier A, Zoete V, Michielin O. Nucleic Acids Res 39 W270-7 (2011)
  2. PDTD: a web-accessible protein database for drug target identification. Gao Z, Li H, Zhang H, Liu X, Kang L, Luo X, Zhu W, Chen K, Wang X, Jiang H. BMC Bioinformatics 9 104 (2008)
  3. Systems pharmacology in drug discovery and therapeutic insight for herbal medicines. Huang C, Zheng C, Li Y, Wang Y, Lu A, Yang L. Brief Bioinform 15 710-733 (2014)
  4. Evolution in an oncogenic bacterial species with extreme genome plasticity: Helicobacter pylori East Asian genomes. Kawai M, Furuta Y, Yahara K, Tsuru T, Oshima K, Handa N, Takahashi N, Yoshida M, Azuma T, Hattori M, Uchiyama I, Kobayashi I. BMC Microbiol 11 104 (2011)
  5. TargetHunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database. Wang L, Ma C, Wipf P, Liu H, Su W, Xie XQ. AAPS J 15 395-406 (2013)
  6. Binding of protein kinase inhibitors to synapsin I inferred from pair-wise binding site similarity measurements. Defranchi E, Schalon C, Messa M, Onofri F, Benfenati F, Rognan D. PLoS One 5 e12214 (2010)
  7. New technologies in computer-aided drug design: Toward target identification and new chemical entity discovery. Tang Y, Zhu W, Chen K, Jiang H. Drug Discov Today Technol 3 307-313 (2006)
  8. Self-subunit swapping chaperone needed for the maturation of multimeric metalloenzyme nitrile hydratase by a subunit exchange mechanism also carries out the oxidation of the metal ligand cysteine residues and insertion of cobalt. Zhou Z, Hashimoto Y, Kobayashi M. J Biol Chem 284 14930-14938 (2009)
  9. In Silico target fishing: addressing a "Big Data" problem by ligand-based similarity rankings with data fusion. Liu X, Xu Y, Li S, Wang Y, Peng J, Luo C, Luo X, Zheng M, Chen K, Jiang H. J Cheminform 6 33 (2014)
  10. Virtual screening: an in silico tool for interlacing the chemical universe with the proteome. Westermaier Y, Barril X, Scapozza L. Methods 71 44-57 (2015)
  11. Large-scale reverse docking profiles and their applications. Lee M, Kim D. BMC Bioinformatics 13 Suppl 17 S6 (2012)
  12. Using reverse docking to identify potential targets for ginsenosides. Park K, Cho AE. J Ginseng Res 41 534-539 (2017)
  13. Computational approaches to find the active binding sites of biological targets against busulfan. Karthick T, Tandon P. J Mol Model 22 142 (2016)
  14. Self-subunit swapping occurs in another gene type of cobalt nitrile hydratase. Liu Y, Cui W, Xia Y, Cui Y, Kobayashi M, Zhou Z. PLoS One 7 e50829 (2012)
  15. Knowledge-based annotation of small molecule binding sites in proteins. Thangudu RR, Tyagi M, Shoemaker BA, Bryant SH, Panchenko AR, Madej T. BMC Bioinformatics 11 365 (2010)
  16. The interprotein scoring noises in glide docking scores. Wang W, Zhou X, He W, Fan Y, Chen Y, Chen X. Proteins 80 169-183 (2012)
  17. RepurposeVS: A Drug Repurposing-Focused Computational Method for Accurate Drug-Target Signature Predictions. Issa NT, Peters OJ, Byers SW, Dakshanamurthy S. Comb Chem High Throughput Screen 18 784-794 (2015)
  18. Computational methods to identify new antibacterial targets. McPhillie MJ, Cain RM, Narramore S, Fishwick CW, Simmons KJ. Chem Biol Drug Des 85 22-29 (2015)
  19. Comparison of ultra-fast 2D and 3D ligand and target descriptors for side effect prediction and network analysis in polypharmacology. Cortés-Cabrera A, Morris GM, Finn PW, Morreale A, Gago F. Br J Pharmacol 170 557-567 (2013)
  20. Histidine 352 (His352) and tryptophan 355 (Trp355) are essential for flax UGT74S1 glucosylation activity toward secoisolariciresinol. Ghose K, McCallum J, Sweeney-Nixon M, Fofana B. PLoS One 10 e116248 (2015)
  21. Preparation and evaluation of anti-Helicobacter pylori efficacy of chitosan nanoparticles in vitro and in vivo. Luo D, Guo J, Wang F, Sun J, Li G, Cheng X, Chang M, Yan X. J Biomater Sci Polym Ed 20 1587-1596 (2009)
  22. Structures of Staphylococcus aureus peptide deformylase in complex with two classes of new inhibitors. Lee SJ, Lee SJ, Lee SK, Yoon HJ, Lee HH, Kim KK, Lee BJ, Lee BI, Suh SW. Acta Crystallogr D Biol Crystallogr 68 784-793 (2012)
  23. A Systematic In-silico Analysis of Helicobacter pylori Pathogenic Islands for Identification of Novel Drug Target Candidates. Nammi D, Yarla NS, Chubarev VN, Tarasov VV, Barreto GE, Pasupulati AMC, Aliev G, Neelapu NRR. Curr Genomics 18 450-465 (2017)
  24. Characterization of peptide deformylase homologues from Staphylococcus epidermidis. Lin P, Hu T, Hu J, Yu W, Han C, Zhang J, Qin G, Yu K, Götz F, Shen X, Jiang H, Qu D. Microbiology (Reading) 156 3194-3202 (2010)
  25. Identification of Potential Drug Targets in Helicobacter pylori Using In Silico Subtractive Proteomics Approaches and Their Possible Inhibition through Drug Repurposing. Ibrahim KA, Helmy OM, Kashef MT, Elkhamissy TR, Ramadan MA. Pathogens 9 E747 (2020)
  26. High tolerance to mutations in a Chlamydia trachomatis peptide deformylase loop. Oey CB, Bao X, Lewis C, Kerrigan JE, Fan H. World J Biol Chem 2 90-97 (2011)
  27. Identification, Genome Sequencing, and Characterizations of Helicobacter pylori Sourced from Pakistan. Fatima A, Ibrahim M, Naseer A, Pervez A, Asad M, Shah AA, Hasan F, Alonazi WB, Ferheen I, Khan S. Microorganisms 11 2658 (2023)
  28. Study on Wangzaozin-A-Inducing Cancer Apoptosis and Its Theoretical Protein Targets. Chen J, Wang S, Lu X. Technol Cancer Res Treat 15 589-596 (2016)


Quick links